Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1833125 | 1.00 | KDM1A (0.39) | KDM1AMTNR1AMTNR1BPLAUCYP1A2 | |
| SCHEMBL1833126 | 1.00 | KDM1A (0.39) | KDM1AMTNR1AMTNR1BPLAUCYP1A2 | |
| SCHEMBL9723648 | 0.81 | HTR2A (0.47) | KDM1AHTR2A | |
| SCHEMBL2171729 | 0.78 | KDM1A (0.47) | KDM1AMTNR1AMTNR1BCYP1A2CYP2D6 | |
| SCHEMBL3588721 | 0.78 | KDM1A (0.47) | KDM1AMTNR1AMTNR1BCYP1A2CYP2D6 | |
| SCHEMBL2171728 | 0.78 | KDM1A (0.47) | KDM1AMTNR1AMTNR1BCYP1A2CYP2D6 | |
| SCHEMBL14837249 | 0.77 | KDM1A (0.39) | KDM1AMTNR1AMTNR1BCYP1A2CYP2D6 | |
| SCHEMBL10622948 | 0.76 | LMNA (0.38) | KDM1AMTNR1AMTNR1BCYP1A2CYP2D6 | |
| SCHEMBL11704380 | 0.73 | MAPT (0.43) | KDM1A | |
| SCHEMBL11704373 | 0.73 | MAPT (0.43) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321287-B1 | 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-8729113-B2 | 4,5-dihydro-oxazol-2yl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8357712-B2 | — | — | 2013-01-22 | — | — | US | disclosed |
| US-8242153-B2 | 4,5-dihydro-oxazol-2YL derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120165294-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | GALLEY GUIDO (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20110144333-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | GALLEY GUIDO | 2011-06-16 | — | — | US | disclosed |
| EP-2321287-A1 | 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100041686-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100029589-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010010014-A1 | 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144333-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | KDM1A 2418/4885MTNR1A 29/4885MTNR1B 26/4885 |
| US-20100029589-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | KDM1A 2418/4885MTNR1A 29/4885MTNR1B 26/4885 |
| US-20100041686-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | KDM1A 2418/4885MTNR1A 29/4885MTNR1B 26/4885 |
| US-20120165294-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | KDM1A 2418/4885MTNR1A 29/4885MTNR1B 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.